Actavis Australia

A Bold New Allergan

Actavis is now Allergan

Actavis plc (NYSE: ACT) has completed the acquisition of Allergan, Inc. (NYSE: AGN) in a cash and equity transaction valued at approximately $70.5 billion.

The combination creates one of the world's top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23 billion anticipated in 2015.

News

News Archive